Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections - New insights into clinical results and treatment practice

Chemotherapy

Volumn 57, Issue 4, 2011, Pages 275-284

  Eckmann, Christian ^a   Heizmann, Wolfgang R ^b   Leitner, Eva ^c   Von Eiff, Christof ^c   Bodmann, Klaus Friedrich ^d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Zentrum für Mikrobiologie und Infektiologie   (Germany)

^c PFIZER INC   (United States)

^d Klinikum Barnim GmbH   (Germany)

Author keywords

Acute Physiology and Chronic Health Evaluation II score; Complicated intra abdominal infections; Complicated skin and skin structure infections; Tigecycline

Indexed keywords

ANTIBIOTIC AGENT; BILIRUBIN; C REACTIVE PROTEIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; LINEZOLID; LIVER ENZYME; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL PRACTICE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CRITICALLY ILL PATIENT; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FEMALE; HUMAN; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; PERITONITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

AGED; ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI; FEMALE; GERMANY; HUMANS; INFECTION; MALE; MIDDLE AGED; MINOCYCLINE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 79960490810     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000329406     Document Type: Article

References (33)

1. Wilcox MH: The tide of antimicrobial resistance and selection. Int J Antimicrob Agents 2009; 34(suppl 3):S6-S10.
2. Nathwani D: New antibiotics for the management of complicated skin and soft tissue infections: are they any better? Int J Antimicrob Agents 2009; 34:S24-S29.
3. Wilcox MH: Tigecycline and the need for a new broad-spectrum antibiotic class. Surg Infect (Larchmt) 2006; 7: 69-80.
4. Hawkey PM, Jones AM: The changing epidemiology of resistance. J Antimicrob Chemother 2009; 64:i3-i10.
5. Boucher HW, Talbot GH, Bradley JS, Edwards JE, et al: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
6. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, et al: Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42: 657-668. (Pubitemid 43271379)
7. Rice LB: Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008; 197: 1079-1081. (Pubitemid 351590040)
8. Barie PS: The cost of failure. Surg Infect (Larchmt) 2008; 9: 313-315. (Pubitemid 351873417)
9. Dryden MS: Skin and soft tissue infection: microbiology and epidemiology. Int J Antimicrob Agents 2009; 34(suppl 1):S2-S7.
10. Kumar A, Roberts D, Wood KE, Light B, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-1596. (Pubitemid 43810035)
11. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, et al: Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 2007; 33: 606-618. (Pubitemid 46474888)
12. Nicolau DP: Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opin Pharmacother 2009; 10: 1213-1222.
13. Seifert H, Dowzicky MJ: A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007). Chemotherapy 2009; 55: 241-252.
14. Kresken M, Leitner E, Brauers J, Geiss HK, et al: Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany. Eur J Clin Microbiol Infect Dis 2009; 28: 83-90.
15. Kresken M, Leitner E, Seifert H, Peters G, et al: Susceptibility of clinical isolates of frequently encountered bacterial species to tigecycline one year after the introduction of this new class of antibiotics: results of the second multicentre surveillance trial in Germany (G-TEST II, 2007). Eur J Clin Microbiol Infect Dis 2009; 28: 1007-1111.
16. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, et al: The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41(suppl 5):S354-S367. (Pubitemid 41170382)
17. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, et al: The efficacy and safety of tigecycline in the treatment of skin and skinstructure infections: results of 2 doubleblind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41(suppl 5):S341-S353. (Pubitemid 41170381)
18. Tanaseanu C, Bergallo C, Teglia O, Jasovich A, et al: Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 61: 329-338. (Pubitemid 351858575)
19. Swoboda S, Ober M, Hainer C, Lichtenstren C, et al: Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 2008; 61: 729-733. (Pubitemid 351321153)
20. Bassetti M, Nicolini L, Repetto E, Rghi E, Del Bono V, Viscoli C: Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis 2010; 10: 287.
21. Vasilev K, Reshedko G, Orasan R, Sanchez M, et al: A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 2008; 62(suppl 1):i29-i40.
22. Poulakou G, Kontopidou FV, Paramythiotou E, Kompoti M, et al: Tigecycline in the treatment of infections from multi-drug resistant Gram-negative pathogens. J Infect 2009; 58: 273-284.
23. Garza-González E, Llaca-Díaz JM, Bosques-Padilla FJ, González GM: Prevalence of multidrug-resistant bacteria at a tertiary-care teaching hospital in Mexico: special focus on Acinetobacter baumannii. Chemotherapy 2010; 56: 275-279.
24. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME: Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008; 62: 895-904.
25. Malangoni MA, Song J, Herrington J, Choudri S, et al: Randomized controlled trial of moxifloxacin compared with piperacillintazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006; 244: 204-211. (Pubitemid 44305534)
26. Chromik AM, Meiser A, Holling J, Sulberg D, et al: Identification of patients at risk for development of tertiary peritonitis on a surgical intensive care unit. J Gastrointest Surg 2009; 13: 1358-1367.
27. De Waele JJ, Hoste EA, Blot SI: Blood stream infections of abdominal origin in the intensive care unit: characteristics and determinants of death. Surg Infect (Larchmt) 2008; 9: 171-177. (Pubitemid 351972570)
28. Roehrborn A, Thomas L, Potreck O, Ebener C, et al: The microbiology of postoperative peritonitis. Clin Infect Dis 2001; 33: 1513-1519. (Pubitemid 34246145)
29. Bergallo C, Jasovich A, Teglia O, Oliva ME, et al: Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009; 63: 52-61.
30. Fernández Canigia L, Kaufman S, Lanata L, Vay C, Giovanakis M, Bantar C: Argentinean Tigecycline Surveillance Group. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina. Chemotherapy 2009; 55: 20-27.
31. Kronvall G, Karlsson I, Walder M, Sörberg M, et al: Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation. J Antimicrob Chemother 2006; 57: 498-505. (Pubitemid 43240203)
32. Bader FG, Schröder M, Kujath P, Muhl E, et al: Diffuse postoperative peritonitis-value of diagnostic parameters and impact of early indication for relaparotomy. Eur J Med Res 2009; 14: 491-496.
33. Hung WY, Kogelman L, Volpe G, et al: Tigecycline-induced acute pancreatitis: case report and literature review. Int J Antimicrob Agents 2009; 34: 486-489.